Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett’s esophagus

Figure 5 Ki67 expression in patients with Barrett’s esophagus at increasing doses of proton pump inhibitor in non-operated patients (group 1) and after anti-reflux surgery (group 2). Group 2 was subdivided into those with and without normal acid reflux. (1) Distal columnar lined esophagus (CLE) near gastroesophageal junction; (2) proximal CLE; and (3) distal squamous epithelium. Medians, 25%-75% quartiles and 10%-90% ranges.